Senti Bio today announced the publication of preclinical data that supports the design of the Phase 1 clinical trial of SENTI-202.
“ IND for SENTI-202, a potential first-in-class logic-gated treatment for AML, cleared by the U.S. FDA; First patient dosing anticipated in the second quarter of 2024 “ “ Cash and anticipated...
Senti Bio Announces Steps to Prioritize Investment in Lead Clinical Program
SOUTH SAN FRANCISCO, Calif., Dec. 22, 2023 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a clinical stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced that it received clearance of its Investigational New Drug (IND) application from the U.S. Food and Drug Administration (FDA) for SENTI-202, an off-the-shelf chimeric antigen receptor natural killer (CAR-NK) cell therapy product candidate designed to selectively target and eliminate CD33 and/or FLT3 expressing hematologic malignancies while sparing healthy bone marrow cells.
“ IND for SENTI-202, a potential first-in-class logic-gated treatment for cancer, on track for clearance in Q4 2023 “ “ Established new strategic collaboration with Celest Therapeutics for...
“ Celest to lead clinical development with technical support from Senti Bio “ “ First patient expected to be enrolled in China in 1H 2024 “ “ Senti Bio eligible to receive up to $156 million in...
Senti Bio Announces Multiple Data Presentations at the Annual Meeting
Senti Bio Announces Multiple Data Presentations at the Society for Immunotherapy of Cancer 2023 Meeting
SOUTH SAN FRANCISCO, Calif., Sept. 26, 2023 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (œSenti Bio), a biotechnology company developing a new generation of cell and gene therapies...
SOUTH SAN FRANCISCO, Calif., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (œSenti Bio), a biotechnology company developing a new generation of cell and gene therapies...